Research. Advocacy. Support.
We advance ovarian cancer research while supporting women and their families.
Know Your Risks
About 20 to 25 percent of women diagnosed with ovarian cancer have a hereditary tendency to develop the disease.
(July 19, 2017) The United States Preventative Services Task Force (USPSTF) has once again recommended against screening for ovarian cancer in asymptomatic, average risk women. The draft statement, which was published on July 18th, does not apply to women who are positive for BRCA1 and BRCA2 genetic mutations, who have a higher risk of developing… More
(July 6, 2017) OCRFA is pleased to announce we have once again earned a 4-star rating from Charity Navigator, America’s largest independent charity evaluator. This rating, the highest awarded by Charity Navigator, demonstrates OCRFA’s continued commitment to maintaining responsible fiscal management practices, as well as transparency and accountability, as we continue to strive toward a cure for ovarian… More
Clinical Trial Shows Rucaparib Significantly Improved Progression-Free Survival in Ovarian Cancer Patients
(July 6, 2017) Clovis Oncology, Inc. recently announced topline data from the confirmatory phase 3 ARIEL3 trial of the drug rucaparib, which successfully achieved the primary endpoint of improved progression-free survival (PFS) by investigator review in each of the three populations studied. Read the press release from Clovis Oncology.
OCRFA’s Super Saturday is a daylong shopping event, presented by QVC, that brings top lu...July 29 @ 12:00 pm - 6:00 pm EDT
OCRFA’s indoor cycling event returns to Tampa, FL on September 9, 2017! Sign up to ride for a ...September 9 @ 10:00 am - 12:00 pm EDT
OCRFA’s indoor cycling event comes for the first time to Springfield, IL, on September 16, 201...September 16 @ 9:00 am - 12:00 pm CDT